These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 26578267)

  • 1. A Novel Allosteric Insulin Receptor-Activating Antibody Reduces Hyperglycemia without Hypoglycemia in Diabetic Cynomolgus Monkeys.
    Bezwada P; Zhao J; Der K; Shimizu B; Cao L; Ahene A; Rubin P; Johnson K
    J Pharmacol Exp Ther; 2016 Feb; 356(2):466-73. PubMed ID: 26578267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. XMetA, an allosteric monoclonal antibody to the insulin receptor, improves glycaemic control in mice with diet-induced obesity.
    Bhaskar V; Lau A; Goldfine ID; Narasimha AJ; Gross LM; Wong S; Cheung B; White ML; Corbin JA
    Diabetes Obes Metab; 2013 Mar; 15(3):272-5. PubMed ID: 23039274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A fully human, allosteric monoclonal antibody that activates the insulin receptor and improves glycemic control.
    Bhaskar V; Goldfine ID; Bedinger DH; Lau A; Kuan HF; Gross LM; Handa M; Maddux BA; Watson SR; Zhu S; Narasimha AJ; Levy R; Webster L; Wijesuriya SD; Liu N; Wu X; Chemla-Vogel D; Tran C; Lee SR; Wong S; Wilcock D; White ML; Corbin JA
    Diabetes; 2012 May; 61(5):1263-71. PubMed ID: 22403294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute Treatment With XMetA Activates Hepatic Insulin Receptors and Lowers Blood Glucose in Normal Mice.
    Bedinger DH; Kieffer DA; Goldfine ID; Roell MK; Adams SH
    J Cell Biochem; 2015 Sep; 116(9):2109-19. PubMed ID: 25808283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon Receptor Blockade With a Human Antibody Normalizes Blood Glucose in Diabetic Mice and Monkeys.
    Okamoto H; Kim J; Aglione J; Lee J; Cavino K; Na E; Rafique A; Kim JH; Harp J; Valenzuela DM; Yancopoulos GD; Murphy AJ; Gromada J
    Endocrinology; 2015 Aug; 156(8):2781-94. PubMed ID: 26020795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective allosteric antibodies to the insulin receptor for the treatment of hyperglycemic and hypoglycemic disorders.
    Issafras H; Bedinger DH; Corbin JA; Goldfine ID; Bhaskar V; White ML; Rubin P; Scannon PJ
    J Diabetes Sci Technol; 2014 Jul; 8(4):865-73. PubMed ID: 24876415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved glucose metabolism in vitro and in vivo by an allosteric monoclonal antibody that increases insulin receptor binding affinity.
    Corbin JA; Bhaskar V; Goldfine ID; Bedinger DH; Lau A; Michelson K; Gross LM; Maddux BA; Kuan HF; Tran C; Lao L; Handa M; Watson SR; Narasimha AJ; Zhu S; Levy R; Webster L; Wijesuriya SD; Liu N; Wu X; Chemla-Vogel D; Lee SR; Wong S; Wilcock D; White ML
    PLoS One; 2014; 9(2):e88684. PubMed ID: 24533136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A selective peroxisome proliferator-activated receptor alpha agonist, CP-900691, improves plasma lipids, lipoproteins, and glycemic control in diabetic monkeys.
    Wagner JD; Shadoan MK; Zhang L; Ward GM; Royer LJ; Kavanagh K; Francone OL; Auerbach BJ; Harwood HJ
    J Pharmacol Exp Ther; 2010 Jun; 333(3):844-53. PubMed ID: 20190014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia.
    Gu W; Yan H; Winters KA; Komorowski R; Vonderfecht S; Atangan L; Sivits G; Hill D; Yang J; Bi V; Shen Y; Hu S; Boone T; Lindberg RA; Véniant MM
    J Pharmacol Exp Ther; 2009 Dec; 331(3):871-81. PubMed ID: 19720878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
    Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
    Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
    Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
    J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential pathway coupling of the activated insulin receptor drives signaling selectivity by XMetA, an allosteric partial agonist antibody.
    Bedinger DH; Goldfine ID; Corbin JA; Roell MK; Adams SH
    J Pharmacol Exp Ther; 2015 Apr; 353(1):35-43. PubMed ID: 25613982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safe and effective use of a glycemic control protocol for neonates in a cardiac ICU.
    Hebson CL; Chanani NK; Rigby MR; Wolf MJ; Deshpande SR; Montegna LM; Maher KO
    Pediatr Crit Care Med; 2013 Mar; 14(3):284-9. PubMed ID: 23392366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing type 2 diabetes: going beyond glycemic control.
    Stolar MW; Hoogwerf BJ; Gorshow SM; Boyle PJ; Wales DO
    J Manag Care Pharm; 2008 Jun; 14(5 Suppl B):s2-19. PubMed ID: 18597582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of tight intraoperative glycemic control during off-pump coronary artery bypass surgery in diabetic and nondiabetic patients.
    Lecomte P; Foubert L; Coddens J; Dewulf B; Nobels F; Casselman F; Cammu G
    J Cardiothorac Vasc Anesth; 2011 Dec; 25(6):937-42. PubMed ID: 21640613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. More satisfied, but why? A pooled patient-level analysis of treatment satisfaction following the initiation of insulin glargine vs. comparators in insulin-naïve patients with type 2 diabetes mellitus.
    Polonsky W; Traylor L; Wei W; Shi R; Ameer B; Vlajnic A; Nicolucci A
    Diabetes Obes Metab; 2014 Mar; 16(3):255-61. PubMed ID: 24028669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between exogenous insulin, endogenous insulin, and glucose in type 2 diabetes patients.
    Janukonyté J; Parkner T; Bruun NH; Lauritzen T; Christiansen JS; Laursen T
    Diabetes Technol Ther; 2015 May; 17(5):335-42. PubMed ID: 25785658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of oxidative stress by a new low-molecular-weight antioxidant improves metabolic alterations in a nonobese mouse diabetes model.
    Novelli M; D'Aleo V; Lupi R; Paolini M; Soleti A; Marchetti P; Masiello P
    Pancreas; 2007 Nov; 35(4):e10-7. PubMed ID: 18090226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous continuous glucose monitoring and dose adjustment decreases glycosylated hemoglobin in spontaneously diabetic cynomolgus monkeys.
    Ishizaka T; Sato T; Kato K; Ohba M; Kimotsuki T; Yasuda M
    Contemp Top Lab Anim Sci; 2003 Sep; 42(5):36-40. PubMed ID: 14510523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoglycemia and hyperglycemia due to insulin antibodies against therapeutic human insulin: treatment with double filtration plasmapheresis and prednisolone.
    Koyama R; Nakanishi K; Kato M; Yamashita S; Kuwahara H; Katori H
    Am J Med Sci; 2005 May; 329(5):259-64. PubMed ID: 15894868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.